+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review

  • ID: 1291955
  • SWOT Analysis
  • May 2015
  • 58 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • CSL Behring
  • Genentech, Inc.
  • Novo Nordisk A/S
  • Pharming Group N.V.
  • Shire Plc
  • ViroPharma Incorporated
  • MORE
Dyax Corp. (DYAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Dyax Corp. (Dyax) is a biopharmaceutical company. It focuses on the development and commercialization of novel biotherapeutics for unmet medical needs in the fields of inflammation and oncology. The company's lead product, ecallantide is approved under the brand name Kalbitor in the US for the treatment of acute attacks of hereditary angioedema in patients 12 years of age and older. Dyax commercializes Kalbitor in the US on its own and through collaborators outside the US. The products and pipeline products of the company utilizes its proprietary phage display technology which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. The company’s pipeline comprises candidates for the treatment of hereditary angioedema. It capitalizes on its technology broadly through the Licensing and Funded Research Program (LFRP). Dyax is headquartered in Burlington, Massachusetts, the US.

Dyax Corp. Key Recent Developments

Apr 29, 2015: Dyax Announces First Quarter 2015 Financial Results
Feb 24, 2015: Dyax Announces Fourth Quarter and Full Year 2014 Financial Results
Feb 18, 2015: Dyax to Participate in Upcoming Investor Conferences
Feb 04, 2015: Dyax to Participate in the Leerink Partners 2015 Global Healthcare Conference
Nov 26, 2013: Dyax Corp. to participate in the 2013 Deutsche Bank BioFEST Conference

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • CSL Behring
  • Genentech, Inc.
  • Novo Nordisk A/S
  • Pharming Group N.V.
  • Shire Plc
  • ViroPharma Incorporated
  • MORE
List of Tables
List of Figures
Section 1 - About the Company
Dyax Corp. - Key Facts
Dyax Corp. - Key Employees
Dyax Corp. - Key Employee Biographies
Dyax Corp. - Major Products and Services
Dyax Corp. - Pharmaceutical Pipeline Products Data
Dyax Corp., Pipeline Products by Therapy Area
Dyax Corp., Pipeline Products by Development Phase
Dyax Corp. - Medical Equipment Pipeline Products Data
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp. - History
Dyax Corp. - Company Statement
Dyax Corp. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Dyax Corp. - Business Description
Dyax Corp. - Corporate Strategy
Dyax Corp. - SWOT Analysis
SWOT Analysis - Overview
Dyax Corp. - Strengths
Strength - Lead Product: Kalbitor
Strength - Licensing and Funded Research Program
Dyax Corp. - Weaknesses
Weakness - History of Losses
Dyax Corp. - Opportunities
Opportunity - Increasing Healthcare Expenditure in the US
Opportunity - Orphan Drug Designation: Kalbitor
Opportunity - Emerging Markets
Dyax Corp. - Threats
Threat - Dependence on Third Party Manufacturers
Threat - Competition and Technological Changes
Threat - Stringent Regulations
Dyax Corp. - Key Competitors
Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals By Year, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals By Type, 2009 to YTD 2015
Dyax Corp., Recent Deals Summary
Section 5 - Company’s Recent Developments
Apr 29, 2015: Dyax Announces First Quarter 2015 Financial Results
Feb 24, 2015: Dyax Announces Fourth Quarter and Full Year 2014 Financial Results
Feb 18, 2015: Dyax to Participate in Upcoming Investor Conferences
Feb 04, 2015: Dyax to Participate in the Leerink Partners 2015 Global Healthcare Conference
Dec 03, 2014: Dyax to Participate in the 25th Annual Oppenheimer Healthcare Conference
Oct 28, 2014: Dyax Announces Third Quarter 2014 Financial Results
Sep 25, 2014: Dyax to Participate in the Leerink Partners Rare Disease Roundtable
Jul 29, 2014: Dyax Announces Second Quarter 2014 Financial Results
Apr 30, 2014: Dyax Announces First Quarter 2014 Financial Results
Apr 16, 2014: Dyax Announces Appointment of Todd Bazemore as Chief Commercial Officer
Section 6 - Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Dyax Corp., Key Facts
Dyax Corp., Key Employees
Dyax Corp., Key Employee Biographies
Dyax Corp., Major Products and Services
Dyax Corp., Number of Pipeline Products by Therapy Area
Dyax Corp., Number of Pipeline Products by Development Stage
Dyax Corp., Pipeline Products By Therapy Area and Development Phase
Dyax Corp. Number of Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Number of Pipeline Products by Development Stage
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp., History
Dyax Corp., Subsidiaries
Dyax Corp., Key Competitors
Dyax Corp., Ratios based on current share price
Dyax Corp., Annual Ratios
Dyax Corp., Interim Ratios
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals By Year, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals By Type, 2009 to YTD 2015
Dyax Corp., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Dyax Corp., Pipeline Products by Therapy Area
Dyax Corp., Pipeline Products by Development Phase
Dyax Corp. Pipeline Products by Equipment Type
Dyax Corp. Pipeline Products by Development Stage
Dyax Corp., Performance Chart (2010 - 2014)
Dyax Corp., Ratio Charts
Dyax Corp., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015
Dyax Corp., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals By Year, 2009 to YTD 2015
Dyax Corp., Medical Equipment, Deals by Type, 2009 to YTD 2015
Note: Product cover images may vary from those shown
4 of 5
XOMA Ltd.
BioInvent International AB
Novo Nordisk A/S
Shire Plc
ViroPharma Incorporated
Genentech, Inc.
Pharming Group N.V.
CSL Behring
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll